Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$22.15 USD
+1.08 (5.13%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $22.16 +0.01 (0.05%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Brokerage Reports
Verona Pharma PLC American Depositary Share [VRNA]
Reports for Purchase
Showing records 141 - 160 ( 192 total )
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Positive Topline Results for Phase 2b Ensifentrine Add-on Therapy for COPD
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q3 Financials Uneventful; Top-line Ensifentrine/COPD Phase 2b Data Around YE
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine/COPD: Ph2b Fully Enrolled; Data Release by YE; Ph3 Starts in 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine/DPI: Positive Interim Ph2 Data at ERS Supports Future Partnership
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q2; Cash Runway into Q2:20; Attractive Valuation in Front of Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Positive DPI Phase 2 Results Expands Ensifentrine COPD Commercial Opportunity
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine/COPD: Key Catalysts in H2; Ph3 to Start in 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine MDI Phase 2 Trial Initiated; Interim Data in H2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Verona Presents Expanded Analysis of Ensifentrine/COPD at ATS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q1; R-D Day Takeaways; Key Data Readouts Anticipated in 2019
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.